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ABSTRACT 
Energy metabolism requires supply of glucose and oxygen. In atherosclerotic 
plaques and cancer tumors, there are local areas with mismatch in demand and 
supply of oxygen and nutrients. The resulting cellular energy imbalance may 
promote energy failure and stimulation of angiogenesis. 
In the first paper, energy metabolites were analyzed in human atherosclerotic 
plaques using high-resolution bioluminescence imaging. Advanced plaques 
were deficient in ATP and glucose, whereas lactate accumulated. ATP and 
glucose deficiency was most pronounced in macrophage-rich areas adjacent to 
the necrotic core. ATP depletion may promote necrotic core expansion and 
progression from stable to unstable plaques. 
In the second paper, reactive oxygen species (ROS) production was studied 
during the development of atherosclerosis in mice. Intracellular ROS levels 
increased before lesions were visible, suggesting that intracellular ROS 
promote initiation of atherosclerosis. In advanced atherosclerotic plaques, 
atorvastatin decreased ROS production in a lipid-lowering independent 
manner. The decrease in ROS may promote stabilization of plaques. 
In the third paper, intussusceptive angiogenesis (IA) was demonstrated in 
human, but not mouse, melanoma metastases. IA may contribute to the growth 
of human melanoma metastases and help explain the poor effect of current 
anti-angiogenic drugs targeted to classic sprouting angiogenesis. We further 
demonstrated that MMP inhibition blocks IA in vitro. 
In summary, this thesis provides evidence of energy deficiency in human 
atherosclerotic plaques, new insights into ROS distribution during 
atherosclerosis development, and finally, evidence of intussusceptive 
angiogenesis in human malignant melanoma metastases. These data may be 
used to further the research into better treatments of atherosclerosis and cancer. 
 Keywords: Energy metabolism, Hypoxia, Reactive oxygen species, 
Intussusceptive angiogenesis 
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Sammanfattning på svenska 
Energimetabolism på cellnivå är beroende av tillgången på syrgas och socker. 
När det blir brist på syrgas (hypoxi) eller socker resulterar det i ett antal 
effekter, varav några är produktion av fria syreradikaler (ROS), och 
kompensatorisk blodkärlsnybildning (angiogenes) för att återställa 
energitillgången. I denna avhandling har jag studerat olika effekter av syrebrist 
och energibrist i ateroskleros och cancer. 
I den första artikeln analyserades mänskliga aterosklerotiska plack 
(åderförkalkning) avseende energimetaboliter. Genom att använda metoden 
bioluminiscens imaging konstaterades att avancerade plack har brist på ATP 
och socker, vilka behövs för att celler ska överleva. Dessutom noterades att 
laktat ansamlades i avancerade plack. 
I den andra artikeln analyserades närvaron av ROS i levande mus-aorta under 
utvecklingen av ateroskleros. Genom att använda bioluminiscens och ROS-
prober påvisades en ökning av ROS innan synliga plack hade utvecklats. 
Dessutom minskade läkemedlet atorvastatin nivåerna av både intracellulärt 
och extracellulärt ROS aterosklerotiska plack, oberoende av lipidnivåer. 
I den tredje artikeln studerades en typ av blodkärlsnybildning kallad 
intussusceptiv angiogenes (eller splitting-angiogenes) i malignt melanom hos 
patienter. Genom att använda immunofluoroscens visade vi att intussusceptiv 
angiogenes förekommer i malignt melanom hos människa, men inte i två 
musmodeller av malignt melanom. Att intussusceptiv angiogenes förekommer 
i mänsklig cancer kan vara en anledning till att nuvarande cancerbehandlingar 
som riktar in sig på blodkärlsnybildning inte är effektiva i de flesta cancertyper. 
Sammanfattningsvis kan sägas att min avhanding har producerat belägg för 
energibrist i avancerade mänskliga aterosklerotiska plack, att intracellulärt 
ROS ökar innan utveckling av ateroskleros, samt förekomsten av splitting-
angiogenes i humant malignt melanom. Dessa data kan i samband med 
framtida forskning förbättra behandlingen av ateroskleros och malignt 
melanom. 
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Normoxia Normal oxygen level. Sometimes refers to 
atmospheric oxygen concentration (21 %). 
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Physoxia Physiological oxygen level. The normal 
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1 INTRODUCTION 
1.1 OXYGEN IN EVOLUTION 
Earth is estimated to be 4.5 billion years old, and life on earth is considered to 
have emerged around 3.7 billion years ago [1]. The conditions of early life 
were entirely anoxic, meaning no oxygen was present, and metabolism taking 
place under these conditions is said to be anaerobic. 
2.3 billion years ago, cyanobacteria started producing oxygen as a byproduct 
of photosynthesis. This oxygen was initially captured by dissolved iron in the 
oceans, and oxygen levels remained low. The oxygen-capture system by iron 
became saturated about 2.25 billion years ago, and the levels of oxygen in the 
oceans and atmosphere started rising in what is called “the great oxygenation 
event”. Even though atmospheric oxygen was a new occurrence, aerobic 
respiration on a limited scale was thought to have previously existed in 
environments with water photolysis [2], or through catalase enzymes which 
convert hydrogen peroxide to oxygen and water [3]. 
Most of the life present during the great oxygenation event would today be 
classified as obligate anaerobes, to which oxygen is toxic. Cells needed to 
adapt to this change in oxygen levels by avoiding it altogether, by developing 
systems to tolerate oxygen, or even using oxygen to extract energy. 
Early eukaryotic cells, which separated their DNA from the rest of the cell by 
using a nuclear membrane, were initially adapted to using only anaerobic 
metabolism [4]. According to the endosymbiosis theory, early eukaryotes 
engulfed a bacterium, a proto-mitochondrion, which got enclosed in a 
membrane in a similar way the DNA of the nucleus was enclosed [5]. A 
symbiosis developed where the bacterium, eventually called mitochondrion, 
utilized oxygen for energy production through respiration, while the host 
eukaryotic cell provided most of the remaining metabolic functions. Over time, 
some of the mitochondrial DNA moved to the cell nucleus, and a translocation 
system for directing proteins to the mitochondrial compartment evolved [6]. 
Even today, the mitochondria keep some of their bacterial features, such as 
unique protein synthesis and circular DNA, and binary fission, which is 
dissimilar to the rest of the eukaryotic cell. Through this symbiosis between 
the mitochondria and early eukaryotic cell, eukaryotes managed to adapt to the 
increased levels of oxygen in the atmosphere. 
Energy metabolism and angiogenesis in atherosclerosis and cancer 
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There are numerous advantages of aerobic metabolism. One such advantage is 
that aerobic metabolism produces considerably more energy than anaerobic 
metabolism. In addition to higher energy production, the presence of oxygen 
enabled more than 1000 new metabolic reactions to develop [7]. In an aerobic 
environment, transmembrane proteins can contain oxygen-rich external 
domains vital for cellular signaling, which in turn is required for multicellular 
life [8]. 
Unicellular organisms and smaller multicellular organisms receive oxygen by 
passive diffusion over their cell membranes. As a multicellular organism 
grows, oxygen is gradually consumed by the outermost cells, which creates an 
oxygen gradient. This oxygen gradient causes the innermost cells to experience 
a lack of oxygen, which in turn results in metabolic issues or cell death. That 
oxygen has a diffusion limit of approximately 200 µm creates a size limit of 
multicellular life unless transport of oxygen is facilitated in some manner. 
Humans are equipped with a closed circulatory system where blood is 
transported through blood vessels powered by the heart, and gas exchange 
takes place in our lungs [9]. 
For oxygen-dependent organisms, hypoxia causes a variety of issues: their 
metabolism cannot function properly, movement is impaired, energy-
consuming processes are halted, damaging reactive oxygen species are 
released, and the cell may ultimately die unless oxygen levels are restored. 
Cells have pre-programmed responses to prevent cellular damage and death 
when they sense hypoxia [10]. They release a variety of signals to induce 
increased oxygen and energy supply, as well as reducing energy-demanding 
processes and changing their energy production to function in an anaerobic 
environment. However, these responses sometimes go awry, and the response 
designed to correct an energy imbalance instead worsens the energy imbalance 
or promotes disease progression. 
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1.2 ENERGY PRODUCTION WITH AND 
WITHOUT OXYGEN 
The main purpose of energy metabolism is to produce ATP (adenosine 
triphosphate), which is a universal energy carrier of the cell. When ATP is used 
to drive various cellular processes, one or two phosphate groups are cleaved 
from the molecule, which releases the stored chemical energy. After ATP is 
consumed, ADP (adenosine diphosphate) or AMP (adenosine monophosphate) 
remains, along with free phosphate groups. 
Glucose is an energy carrier that may easily be moved between cells within an 
organism and can be stored polymerized as glycogen. In all the upcoming 
descriptions of energy metabolism, we will use glucose as the starting point, 
even though many other energy substrates, such as amino acids and fatty acids, 
can be quickly metabolized and inserted into various parts of the metabolic 
pathways. 
1.2.1 GLYCOLYSIS 
All eukaryotes are equipped with a metabolic system called glycolysis [11], 
where one glucose molecule is broken down into two molecules of pyruvate. 
Glycolysis generates 2 ATP molecules from the original glucose molecule, or 
3 ATP if the source is glycogen [12]. Compared to respiration, this is a very 
small energy gain; however, the flux through the glycolytic pathway is very 
rapid, meaning that energy can quickly be mobilized, given an adequate supply 
of glucose or glycogen. 
Glycolysis takes place in the cell cytoplasm, and the process is anaerobic, i.e., 
it does not require oxygen. In addition to creating pyruvate, NAD+ 
(nicotinamide adenine dinucleotide) is reduced to NADH during glycolysis. 
The available pool of NAD+ in the cytoplasm is fairly small, which means it 
needs to be restored if glycolysis is taking place rapidly. NAD+ can be restored 
anaerobically by conversion of pyruvate into lactate by lactate dehydrogenase 
(LDH). Alternatively, the electrons of NADH can be transferred into the 
mitochondria by the help of the malate-aspartate shuttle, after which 
mitochondrial NAD+ can be restored by oxidative phosphorylation in the 
presence of oxygen, which results in the production of ATP.  
After pyruvate is produced through glycolysis, it is transported into the 
mitochondrial matrix, where it is oxidized into acetyl-CoA (acetyl coenzyme 
A). 
Energy metabolism and angiogenesis in atherosclerosis and cancer 
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Figure 1 - Glycolysis pathway. Glucose or glycogen is metabolized into Acetyl-CoA or lactate 
while producing 2-3 ATP depending on the glucose source. Orange text signifies enzymes. Red 
text signifies low energy compounds and green text signifies high energy compounds. Blue text 
signifies redox pairs. All content inside the gray box takes place twice per original glucose 
molecule. All reactions occur in the cytosol unless specified otherwise. 
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1.2.2 CITRIC ACID CYCLE 
Acetyl-CoA enters the citric acid cycle (Figure 2) with the aid of citrate 
synthase, which converts it into citrate. Once in the cycle, the citrate is 
metabolized by a series of enzymes which create a variety of compounds along 
the way. Several steps in the citric acid cycle create NADH, which is later used 
in oxidative phosphorylation. The reaction of succinate into fumarate takes 
place with the aid of complex II, which also reduces ubiquinone (Q) to 
ubiquinol (QH2). This process requires functional oxidative phosphorylation, 
and without it, the citric acid cycle will cease to regenerate the substances 
needed to continue the cycle. 
 
Figure 2 - In the citric acid cycle, the acetyl part of acetyl-CoA is attached to oxaloacetate to 
generate citric acid. Through a series of reactions, the two extra carbons are oxidized into CO2, 
recreating citrate, while also producing NADH from NAD+, as well as other energy-containing 
compounds. NADH and QH2 can further be processed through oxidative phosphorylation. 
Orange text signifies enzymes. Red text signifies low energy compounds and green text signifies 
high energy compounds. Blue text signifies redox pairs. 
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1.2.3 OXIDATIVE PHOSPHORYLATION 
Once NADH is produced in the citric acid cycle, it reacts with complex I of 
the electron transport chain to release two electrons, which are deposited on Q 
to form QH2 while oxidizing NADH to NAD+ and H+. The electrons of QH2 
are passed between complex III and IV, which both use the energy of the 
electrons to drive an H+ pump, transporting H+ from the matrix into the 
intermembrane space of the mitochondria. In the end, the electrons are 
deposited on oxygen (the terminal electron acceptor), which produces water as 
the end product. 
In addition to using NADH as a source of electrons, succinate, which is part of 
the citric acid cycle, is also used as an electron source for the electron transport 
chain. Succinate reacts with complex II, which oxidizes succinate to fumarate, 
and passes the electrons to Q to produce QH2, whose electrons are shuttled 
through complex III and IV, and pumps H+ from the matrix into the 
intermembrane space. 
The H+ gradient which is built up by the electron transport chain can then be 
utilized by ATP synthase, allowing H+ back into the matrix in a controlled 
manner while facilitating the reaction of ADP and a phosphate group, 
producing ATP [13]. When the entire pathway from glucose into carbon 
dioxide and water is taken into account, oxidative phosphorylation produces 
approximately 30-38 molecules of ATP [14, 15] from each molecule of 
glucose.
 
Figure 3 - Oxidative phosphorylation. Electrons from NADH are transferred to QH2 in complex 
I accompanied by the transport of H+ into the intermembrane space. Concurrently, succinate 
is converted to fumarate in complex II, also producing QH2. The electrons of QH2 are passed 
though complex III and IV accompanied by the transport of H+ into the intermembrane space, 
finally reducing oxygen to produce water. The proton gradient is used by ATP synthase to 
produce ATP. Orange text signifies enzymes. Red text signifies low energy compounds and 
green text signifies high energy compounds. Blue text signifies redox pairs. 
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1.2.4 OTHER MEANS OF ENERGY PRODUCTION 
The pathways mentioned so far (i.e., glycolysis, the citric acid cycle, and 
oxidative phosphorylation), are important in energy metabolism. However, 
there are also other metabolic pathways which can be utilized to generate 
energy. 
Fatty acids can be broken down by a process called beta-oxidation. In short, 
free fatty acids are transported to the mitochondrial matrix by the aid of 
membrane transport proteins, after having been conjugated to CoA, to form 
fatty acyl-CoA. Once inside the mitochondrial matrix, beta-oxidation takes 
place, where carbon atoms are cleaved in pairs from the fatty acid chain to 
form acetyl-CoA until the entire chain has been consumed [16]. Acetyl-CoA 
can then be fed into the citric acid cycle and processed from there following 
previously mentioned pathways. Each cycle of beta-oxidation produces 
approximately 14 ATP and is dependent on oxidative phosphorylation to 
function. 
Amino acids can de deaminated, where the amino group is removed from the 
rest of the carbon skeleton. If the remaining part of the amino acid is 
glucogenic, it can be metabolized into citric acid cycle intermediates, which 
may be broken down for energy or go through gluconeogenesis. If the amino 
acid is ketogenic, it may be converted to acetyl-CoA, which in turn can 
generate energy, or be used in ketogenesis to produce ketone bodies [17].  
During periods of low food intake, fasting, or starvation, the liver may create 
ketone bodies to supply the body with energy [18]. Mainly muscle, heart, and 
brain tissue will use ketone bodies as an energy source through re-conversion 
into acetyl-CoA, which is metabolized through the citric acid cycle and 
downstream pathways to produce energy.  
1.2.5 OXYGEN REQUIREMENTS FOR ENERGY 
PRODUCTION 
Oxidative phosphorylation is the major component of human energy 
metabolism which requires oxygen. Most of our energy metabolism is reliant 
on oxidative phosphorylation to restore redox balance and produce ATP. 
Without oxidative phosphorylation, the citric acid cycle cannot restore 
fumarate from succinate, and other reduced species such as NADH start to 
accumulate. Glycolysis is the only truly anaerobic pathway able to 
continuously generate energy in human cells, and it generates only 2-3 ATP 
per glucose molecule, compared to the 30-38 ATP that can be created through 
full respiration [14, 15]. 
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1.3 INSUFFICIENT OXYGEN SUPPLY – 
HYPOXIA 
In the atmosphere, the oxygen concentration is 21 %, which is called normoxia. 
The normal level of oxygen in a certain tissue is called physoxia, which is 
much lower than 21 %. Some examples of oxygen levels in different parts of 
the body are given in Table 1. 
Tissue Physoxia level  
(% oxygen) 
Atmosphere 21.1 % 
Air in the alveoli 14.5 % 
Arterial blood 13.2 % 
Venous blood 5.3 % 
Cell 1.3-2.5 % 
 
When oxygen levels are much lower than normal for a certain tissue, it is called 
hypoxia, the deficiency of oxygen. Cells have a pre-programmed response to 
hypoxia to adapt and survive, and it usually starts to occur when oxygen levels 
reach around 5% and gradually increases as oxygen levels fall [20]. Currently, 
hypoxia is defined as an oxygen concentration of less than 2% [21]. 
Hypoxia is present in a variety of physiological as well as pathological 
conditions. Embryo development, for example, is entirely dependent on 
functional hypoxic signaling to survive [21, 22]. Hypoxia is also required to 
keep stem cells in an undifferentiated state [23]. Local tissue hypoxia is also a 
feature of several pathologies, such as tumors [24], atherosclerotic plaques 
[25], and chronic wounds [26]. 
On a systemic level, acute hypoxia in the arterial blood is sensed by 
chemoreceptors in the carotid body, which induce hyperventilation to alleviate 
the lack of oxygen [27]. Chronic hypoxia is compensated by increased 
production of erythropoietin (EPO) in the kidney, stimulating the production 
Table 1 - Oxygen concentrations in different organs and tissues. Values collected from Correau 
et al. [19]. 
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of red blood cells for more efficient extraction of oxygen from the air in the 
lungs, and an increased oxygen transport capacity [28]. 
When hypoxic stress is detected by the cell, the hypoxic response is triggered. 
In mammals, this is mediated mainly by hypoxia-inducible factors (HIFs), 
which are transcription factors that alter the expression of more than 100 genes 
[29]. The overall purpose of the hypoxic response is to promote survival of the 
cell by downregulating energy-demanding processes, upregulating anaerobic 
metabolism, and promoting energy restoration to the tissue in which the cell 
resides. 
1.3.1 HYPOXIA INDUCIBLE FACTORS 
HIF, a heterodimer, is a protein consisting of two different subunits, HIFα and 
HIFβ. HIFα is oxygen labile, meaning it breaks down in the presence of 
oxygen, while HIFβ (also called ARNT) is stable and continuously expressed 
regardless of the oxygen level. 
 HIFα   + HIFβ 
HIF-1 HIF1α HIFβ 
HIF-2 HIF2α HIFβ 
HIF-3 HIF3α HIFβ 
 
HIFs bind to hypoxia response elements (HRE) on DNA to convey their 
transcriptional effects. While HIF-1 and HIF-2 bind to the same HRE, their 
target genes are slightly different [30]. HIF-3, on the other hand, negatively 
regulates HIF1 and HIF-2 either by direct competition or by disrupting the 
interaction of HIFα and HIFβ subunits [31]. 
The effects of HIF-1 generally include a shift toward anaerobic glycolysis by 
upregulation of glycolytic enzymes, such as hexokinase, phosphofructokinase, 
aldolase, and many others. HIF-1 also upregulates glucose transporters 
(GLUTs) and prevents the entry of pyruvate into the citric acid cycle by 
upregulation of pyruvate dehydrogenase kinase 1 (PDK1), which stops the 
conversion of pyruvate into acetyl-CoA by phosphorylating pyruvate 
dehydrogenase (PDH) [32]. Additionally, LDH is upregulated, which 
Table 2 - HIF consists of an alpha and beta subunit. The alpha subunit exists in several isoforms 
and is oxygen labile, while the beta subunit is oxygen stable and continuously expressed. 
Energy metabolism and angiogenesis in atherosclerosis and cancer 
10 
promotes the conversion of pyruvate into lactate while restoring NAD+ to 
allow further glycolysis. 
The effects of HIF increase cellular import of glucose, flux through the 
glycolytic pathway and finally conversion into lactate. Since the flow of 
metabolites into the citric acid cycle is prevented, the need for oxidative 
phosphorylation, and subsequently, the need for oxygen is reduced. 
Not only does HIF signaling promote immediate survival through metabolic 
redirection for energy production, but also redirects parts of the glucose 
metabolism into the pentose phosphate pathway (PPP) to be used for DNA and 
RNA synthesis, as well as the production of NADPH which is used to restore 
antioxidant function [33]. 
The effects mentioned so far have been centered around the cellular adaptation 
to hypoxia. Ideally, hypoxia needs to be resolved, and this is where the cell 
needs to affect its surroundings. HIF signaling promotes the production of 
vascular endothelial growth factor (VEGF) [29] which induces angiogenesis, 
the formation of new blood vessels, to restore oxygen supply and resolve the 
hypoxic stress on the cell. 
HIF signaling is tightly connected to inflammation. In most inflammatory 
conditions, cells experience hypoxia due to lower circulation, and high 
metabolic demand of infiltrating immune cells. During inflammation, nuclear 
factor kappa B (NF-κB) is activated through a separate pathway, as well as by 
HIF. Interestingly, NF-κB also upregulates HIF1α the transcription in 
macrophages [34]. 
1.3.2 REGULATION OF HIF 
When oxygen is present, prolyl hydroxylase domain (PHD) proteins 
hydroxylate HIFα at two conserved proline residues [35]. This hydroxylation 
makes an E3 ubiquitin ligase identify HIFα as marked for proteasomal 
degradation, meaning HIFα is degraded in the presence of oxygen [36]. 
PHDs, in turn, are directly regulated by oxygen. PHDs require α-ketoglutarate 
as a substrate, which is an intermediate in the citric acid cycle. Other 
intermediates of the citric acid cycle, such as fumarate and succinate, instead 
inhibit PHDs, which allows for fine-tuning of the pathway depending on 
metabolic status. Additionally, during moderate hypoxic conditions of 
approximately 1.5 % oxygen, mitochondria produce reactive oxygen species 
(ROS) from mitochondrial complex III, which then inhibit PHD activity, and 
thus stabilize HIFα [37]. 
Matias Ekstrand 
11 
Factor-inhibiting HIF1α (FIH1) is another oxygen-dependent enzyme which 
hydroxylates HIF1α at an asparagine residue, which in turn prevents HIF1α 
from binding to its coactivators [38, 39]. There are other regulators of HIF as 
well, such as sirtuins, which modulate HIF depending on the cellular redox 
state [40]. 
1.3.3 OTHER OXYGEN SENSING PATHWAYS 
While HIFs are the most known oxygen-sensing pathway, there are also other 
pathways that cooperate to induce hypoxia-tolerance. These include the kinase 
mammalian target of rapamycin (mTOR), the unfolded protein response 
(UPR), and NF-κB [41, 42].  
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1.4 REACTIVE OXYGEN SPECIES 
Reactive oxygen species (ROS) are reactive oxygen-containing compounds, 
which are created as a byproduct of cellular metabolism or intentionally 
formed as part of signaling pathways or cellular defense.  
The existence of ROS in biology has been known for approximately 60 years 
[43]. Initially, the presence of ROS was regarded as an exclusively deleterious 
process, leading to oxidative damage, cancer, and aging. However, that view 
was later revised, as ROS were shown to be part of normal physiological 
processes and signaling [44]. 
There are many types of ROS. Some examples are superoxide (O2−), hydrogen 
peroxide (H2O2), hydroxyl radicals (•OH), singlet oxygen (O2•) and 
peroxynitrite (ONOO−) [44]. Each type of ROS functions slightly differently 
in terms of location, reactivity, as well as signaling pathways and diseases they 
are involved in.  
1.4.1 REACTIVE OXYGEN SPECIES IN 
PHYSIOLOGICAL CELL SIGNALING 
Production of extracellular ROS is part of the pathogen defense and other 
signaling functions. NADPH oxidases (Nox) create superoxide or hydrogen 
peroxide aimed toward the extracellular space or intracellular phagosomes. 
Nox is expressed in 5 isoforms in a variety of cell types. Nox1 is expressed in 
epithelial cells of the colon (wound healing), Nox2 is expressed in 
macrophages and neutrophils (pathogen defense) [44], Nox3 is expressed in 
the inner ear (otolith production), Nox4 is expressed in kidney (stem cell 
maintenance), and Nox5 is expressed in testis (sperm maturation) [45]. 
Furthermore, nitric oxide synthase (NOS) is present in endothelial cells, 
generating nitric oxide, which regulates the vascular tone of smooth muscle 
around the vessel. Xanthine synthase is a hepatic enzyme which is released 
into the blood, converting hypoxanthine into xanthine and finally, uric acid 
while also produces superoxide and hydrogen peroxide [46].  
Intracellular ROS is produced mainly by mitochondria. Both mitochondrial 
complexes I and III produce both baseline ROS, as well as increased ROS to 
direct intracellular signaling [47]. Intracellular ROS affect enzymes in various 
signaling pathways, such as ASK1 and PI3K (proliferation, survival signaling) 
[48, 49], IRP (iron homeostasis) [50], ATM (DNA damage repair and 
autophagy) [51], and Ref-1 (antioxidant response) [52]. ROS is also involved 
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in mitochondrial hypoxia signaling, as seen in chapter 1.3.2 “Regulation of 
HIF”. 
ROS exerts its physiological effects through an oxidative interface, described 
as redox-sensitive cysteine and methionine residues which ROS may interact 
with [53]. Depending on what degree the residues are oxidized to, the 
modifications are temporary (sulfenic acid, -SOH), hard to reverse (sulfinic 
acid, -SO2H), or nearly irreversible (sulfonic acid, -SO3H). The oxidative 
changes induce conformational changes of the proteins, as well as formation 
of intra-protein disulfide bridges in the case of sulfenic acid. The oxidative 
changes to cysteine and methionine residues on proteins can be reversed by 
thioredoxin, peroxiredoxin, and methionine sulfoxide reductase [54, 55]. 
1.4.2 NEUTRALIZATION OF REACTIVE OXYGEN 
SPECIES 
The neutralization, or scavenging, of ROS is essential for protecting the cell 
against deleterious effects since an accumulation of ROS can damage 
intracellular and/or extracellular components. 
Superoxide, one of the most potent types of ROS, is scavenged by superoxide 
dismutase (SOD) which converts superoxide into hydrogen peroxide. There 
are different isoforms of SOD, all of which have different localizations. SOD1 
is cytoplasmic, SOD2 is mitochondrial, and SOD3 (also known as ecSOD) is 
extracellular [56]. 
Hydrogen peroxide, in turn, is converted into water and molecular oxygen by 
the enzyme catalase, which can be intracellular or extracellular [57]. In 
addition to neutralizing hydrogen peroxide, membrane-associated catalase also 
scavenges peroxynitrite and oxidizes nitric oxide [58]. 
Glutathione (GSH) is a soluble antioxidant, able to neutralize both hydrogen 
peroxide and lipid peroxides through intracellular or extracellular glutathione 
peroxidases (GPx) [59, 60]. After oxidation of glutathione, it may be reduced 
by NADPH to restore its anti-oxidative function [61]. 
1.4.3 EXCESSIVE ROS IN PATHOLOGICAL 
CONDITIONS 
While a baseline of ROS is required for basic cellular functions, an excess of 
ROS results in potentially harmful effects. ROS has been shown to be 
connected to a variety of diseases, such as cardiovascular disease, autoimmune 
diseases, neurological disorders, and cancer [62]. 
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An important aspect of ROS is its pro-inflammatory features. Extracellular 
ROS increases the adhesion of leukocytes to endothelium, meaning that 
immune cells are recruited to sites where ROS is present [63]. Moreover, 
intracellular ROS promotes an inflammatory macrophage phenotype [64]. This 
is especially important in diseases such as atherosclerosis, where high 
intracellular and extracellular ROS levels promote an ever-increasing 
inflammatory state [65]. 
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1.5 TRANSPORT OF OXYGEN TO CELLS – 
BLOOD VESSELS 
Unicellular organisms get access to oxygen through diffusion from the 
environment directly into the cell. Bigger multicellular organisms require a 
transport system for oxygen. In humans, this is accomplished by the vascular 
system. In the lungs, oxygen binds to hemoglobin in red blood cells which 
travel through the vascular system into the semi-permeable capillaries, where 
oxygen is released to the surrounding tissues. The vascular system is adapted 
so that capillaries are dispersed through the various tissues to provide the cells 
of the body with sufficient oxygen supply. Therefore, almost all cells in the 
body are situated within 100-200 µm from a capillary [66]. 
1.5.1 VASCULOGENESIS AND ANGIOGENESIS 
The vascular system is created in two distinct phases – vasculogenesis and 
angiogenesis. Vasculogenesis is the de novo formation of blood vessels, where 
individual endothelial cells create a vessel. Vasculogenesis takes place in early 
development to establish the base of the vascular system of the growing 
embryo. In vasculogenesis, endothelial progenitor cells are recruited from the 
bone marrow to the tissue, where they form new vessels [67]. 
Once the initial embryonic vascular network is established, it is further 
expanded via angiogenesis. Angiogenesis is the formation of new blood 
vessels from existing vessels. There are two forms of angiogenesis, sprouting 
angiogenesis and intussusceptive (or splitting) angiogenesis. Sprouting 
angiogenesis is the outgrowth of a new branch from an existing vessel, and 
intussusceptive angiogenesis is the splitting of one vessel into two parallel 
vessels. 
1.5.1.1 SPROUTING ANGIOGENESIS 
Observations of what would later be called angiogenesis were first described 
around 1787 by a surgeon named John Hunter [68]. The angiogenesis observed 
was later termed sprouting angiogenesis. Sprouting angiogenesis has been the 
main focus of angiogenesis research, being the majority of the almost 100.000 
scientific publications about angiogenesis that can currently be found. 
Sprouting angiogenesis is dependent mainly on the signaling pathway of 
VEGF. When tissue requires better vascularization, VEGF is released by 
hypoxic cells. VEGF is sensed by VEGF receptors on endothelial cells of 
nearby vessels. When there exist enough stimuli to trigger sprouting, a tip cell 
is formed (Figure 4). The tip cell is described as having many filopodia 
(reminiscent of finger-like appendices), which sense angiogenic signals and 
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directs the growing sprout [69]. The tip cell is followed by stalk cells which 
are proliferative and phalanx cells which connect the sprout to the original 
vessel. The sprouts eventually fuse with other sprouts or blood vessels in the 
area, after which blood flow can be established inside the newly formed vessel. 
There are a number of other factors which impact sprouting angiogenesis, such 
as fibroblast growth factors (FGF) [70], transforming growth factor β (TGF-β) 
[71] and platelet-derived growth factor (PDGF) [72, 73], matrix 
metalloproteinases (MMPs) [74], and many others [75, 76]. Many of these 
factors are directly or indirectly connected to VEGF signaling pathways. 
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Figure 4 - Schematic image of sprouting angiogenesis and intussusceptive angiogenesis. A. 
Sprouting angiogenesis is characterized by the outgrowth of a sprout from an existing vessel. 
B. Intussusceptive angiogenesis forms tissue pillars through the vessel, splitting it into two. C. 
The sprout is led by a top cell which directs the sprout toward a gradient of VEGF, and the cells 
of the stalk behind it are proliferative. D. The intussusceptive pillar consists of endothelium 
connecting both ends of the vessel, forming the outside of the pillar. Smooth muscle cells and 
collagens are inside the pillar.  
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1.5.1.2 INTUSSUSCEPTIVE ANGIOGENESIS 
Intussusceptive angiogenesis was discovered as a separate form of 
angiogenesis in 1986 by Burri et al. [77, 78]. However, features of 
intussusceptive angiogenesis were described already in 1895 in fish gills [79], 
and in 1950 in embryonic lungs [80].  
A literature search reveals that the field of intussusceptive angiogenesis 
research is small, consisting of less than 200 articles in total. In comparison, 
sprouting angiogenesis (often just referred to as angiogenesis) has articles 
published in the magnitude of 20,000-100,000 depending on search terms and 
location of keywords (Table 3). 
Search term Location PubMed Scopus 
“splitting AND angiogenesis” OR 
“intussusceptive AND angiogenesis” 
Title/abstract 178 198 
“splitting angiogenesis” OR 
“intussusceptive angiogenesis” 
Title 39 41 
“sprouting AND angiogenesis” Title/abstract 2642 2646 
“sprouting AND angiogenesis” Title 150 158 
“angiogenesis” Title/abstract 90,935 97,984 
“angiogenesis” Title 23,825 26,979 
 
The first step in intussusceptive angiogenesis is characterized by the formation 
of a thin tissue pillar, which extends across the lumen of the vessel (Figure 4). 
The pillar is thin, 2-4 µm in diameter. A schematic drawing of the different 
steps in intussusceptive angiogenesis is shown in Figure 1 of Paper III. The 
first step of intussusception is the formation of a pillar across the vascular 
lumen. As the pillar matures, collagen bundles are pulled into the core [81]. 
Pericytes, smooth muscle cells, and fibroblasts cells then migrate into the pillar 
to aid in maturation until it resembles the vascular surroundings [82]. More 
pillars usually form downstream of the initial pillar, which finally fuse to 
separate the vessel longitudinally into two new vessels [83]. During the process 
Table 3 - Literature search for intussusceptive angiogenesis and sprouting angiogenesis on 
PubMed and Scopus (accessed on 2019-09-18). 
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of intussusceptive angiogenesis, basement membranes must be remodeled by 
enzymes such as MMPs [84]. Without remodeling, the basement membrane is 
stiff, causing pericytes, smooth muscle cells, and fibroblasts to be locked in 
place around the vessel. 
Traditionally, intussusceptive angiogenesis has been analyzed by corrosion 
casting along with scanning electron microscopy (SEM) [78]. This method 
removes all tissues surrounding the vascular lumen, leaving an imprint of the 
inside of the blood vessel, enabling identification of pillars. Another method 
of analyzing intussusceptive angiogenesis is transmission electron microscopy 
(TEM). TEM requires a large time investment and hundreds of tissue sections 
and is feasible only in tissues with a high density of intussusceptive 
angiogenesis [85]. A less time-consuming method of identifying 
intussusceptive pillars is to use immunofluorescence. By using a combination 
of markers for endothelium, collagens, and pericytes/smooth muscle, it is 
possible to identify pillars in a normal fluorescence microscope. Identified 
pillars may be 3D reconstructed by confocal microscopy to verify the structure 
since pillars can only be verified by 3D imaging [82]. 
The mechanisms of intussusceptive angiogenesis are not fully elucidated. Due 
to pillars forming across a functional vascular lumen, the presence of a growth 
factor gradient is unlikely, since any growth factor transferred into the blood 
would immediately be whisked away [85]. There are studies implicating that 
nitric oxide signaling is involved in the switch from sprouting to 
intussusception [86], and blood flow dynamics are highly indicative of 
intussusceptive angiogenesis, with the majority of pillars occurring close to 
vessel bifurcations [83]. Indeed, intussusceptive angiogenesis is induced in 
skeletal muscle after exercise or electrical stimulation, both of which increase 
blood flow and nitric oxide signaling [87, 88]. Other factors thought to be 
involved in intussusceptive angiogenesis are TIE-receptors [89] and basic 
fibroblast growth factor (bFGF) [90]. Furthermore, inhibition of Notch 
signaling has been shown to enhance pillar formation [91], mediated through 
stromal cell-derived factor-1 (SDF‐1, also known as CXCL12) [92] signaling, 
which mobilizes bone marrow-derived cells (BMDCs). The involvement of 
BMDCs indicates that a functioning immune system may be required for pillar 
formation. 
It has been suggested that during embryonal and postnatal development, 
sprouting angiogenesis establishes the vascular network into a growing tissue 
in an invasive manner, after which the intussusceptive expansion and 
remodeling phase takes place [93, 94]. Sprouting is slower and more energy-
consuming, whereas intussusceptive angiogenesis is faster and more efficient, 
allowing rapid organ growth.  
Energy metabolism and angiogenesis in atherosclerosis and cancer 
20 
  
Matias Ekstrand 
21 
2 AIMS 
The overall aim of this thesis is to study the effects of deranged energy 
metabolism in atherosclerosis and cancer. 
Paper I 
• To address the hypothesis that energy failure develops in the 
core of human advanced atherosclerotic plaques. 
Paper II 
• To investigate if intracellular and extracellular levels of 
reactive oxygen species (ROS) within the mouse aorta 
increase before or after diet-induced lesion formation. 
• To investigate if intracellular and extracellular ROS 
correlates to cell composition in atherosclerotic lesions. 
• To investigate if intracellular and extracellular ROS levels 
within established atherosclerotic lesions can be reduced 
through lipid-lowering by diet or atorvastatin. 
Paper III: 
• To address the hypothesis that intussusceptive angiogenesis 
promotes growth of human tumors. 
• To establish a model to elucidate the cellular and molecular 
mechanisms behind intussusceptive angiogenesis with the 
further aim of identifying potential drug targets.  
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3 HYPOXIA, ENERGY METABOLISM, AND 
ATHEROSCLEROSIS 
3.1 THE HEALTHY VASCULAR WALL 
Blood vessels are more than just pipes in which blood is transported. Vessels 
are built from a variety of different cell types, all of which require oxygen and 
nutrients to function. The vascular wall is divided into the intima, media, and 
adventitia (Figure 5). 
The innermost, intimal, layer (or tunica intima) consists of a single layer of 
endothelial cells and sub-endothelial tissue. The function of the endothelial 
cells is to keep the blood inside the lumen and prevent it from coming into 
direct contact with the tissue. If the endothelium is damaged, blood will clot to 
cover the wound and repair the damage [95]. The medial layer (or tunica 
media), consists mainly of smooth muscle cells, elastin, and collagen, which 
provide contractile force to the vessel [96]. The outermost layer is called the 
adventitial layer (or tunica adventitia) and consists of collagen and other 
extracellular matrix components which give stability to the vessel, as well as a 
point to attach the vessel to other structures. The adventitia also contains blood 
vessels (vasa vasorum) and progenitor cells [97]. 
The cells of the vascular wall receive oxygen and nutrients from two sources; 
directly from blood in the vascular lumen, and from the vasa vasorum [98]. 
The vasa vasorum is a vascular network in the adventitia and, in large arteries, 
the outer third of the media [99]. The vasa vasorum are functional end arteries, 
meaning they have low anastomosis (few cross-connections) and are sensitive 
to occlusion. Even in the healthy vascular wall, the supply of oxygen and 
glucose is strained with low concentrations in the mid-media, making the 
vascular wall vulnerable to perturbations [100, 101]. 
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Figure 5 - The healthy vascular wall. Reprinted from Leppänen et al. with permission[102]. 
Oxygen and nutrients are supplied directly from luminal blood and from vasa vasorum. 
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3.2 DEVELOPMENT OF ATHEROSCLEROSIS 
Atherosclerosis is one of the leading causes of death and disability worldwide 
[103]. Atherosclerosis is more prevalent in men, who develop it at an earlier 
age, than women, who women develop atherosclerosis mainly after menopause 
[104]. Some risk factors which contribute to the development of 
atherosclerosis are high cholesterol and lipoprotein levels, high blood pressure, 
smoking, overweight, insulin resistance, and diabetes [105]. 
Atherosclerosis is characterized by the accumulation of lipids and 
macrophages in the intimal layer of the vascular wall, causing a narrowing of 
the vascular lumen by a plaque (Figure 6). The narrowing of the lumen results 
in impaired blood supply to organs and tissues. If the plaque ruptures in a 
coronary or carotid artery, the resulting blood clots may cause myocardial 
infarctions or stroke. Atherosclerosis has a subclinical or “silent” phase with 
no clinical manifestations, which may last for years or decades [106]. 
Atherosclerotic plaques are classified according to Stary [107]. Early plaques 
(stage I and II) contain a few macrophages in the intima and some intracellular 
lipid accumulation. Intermediate plaques (stage III) have more accumulated 
extracellular lipids in addition to an increase in macrophages. Advanced 
plaques (stage IV to VI) contain a pronounced accumulation of macrophages 
and a necrotic core of extracellular lipids. 
3.2.1 INITIATION OF ATHEROSCLEROSIS 
One of the initial steps in the development of atherosclerosis is the recruitment 
of monocytes into the intima. The monocytes differentiate into macrophages, 
which take up modified lipoproteins containing lipids, and become 
macrophage foam cells [108]. The theories surrounding the initiation of 
atherosclerosis have developed over the years, but a common theme is the 
presence of oxidized LDL. 
The response to injury hypothesis postulated in 1977, states that atherosclerosis 
is initiated by an injury to the vascular endothelium [109]. Examples of injuries 
are high blood glucose, hyperlipidemia, hypertension, turbulent blood flow, 
reactive oxygen species, or a combination. The injury results in the recruitment 
of monocytes to clean up the injury site. The monocytes accumulate lipids, 
including oxidized LDL, resulting in development of fatty streaks, which is an 
early event in the development of atherosclerosis. The response to injury 
hypothesis is however questioned, mainly due to the injury being vaguely 
specified, and that lipids accumulate before monocyte recruitment in animal 
models [110].  
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Figure 6 – Advanced atherosclerotic plaque. Modified from Leppänen et al. with permission 
[102]. Note accumulation of macrophage foam cells and necrotic cells in the core of the plaque. 
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The oxidative modification hypothesis was postulated in 1989 [111]. It states 
that oxidized LDL is responsible for recruiting monocytes to the intima. 
Monocytes phagocytose oxidized LDL and are transformed into macrophage 
foam cells. A strength of this model is that it does not require endothelial 
damage, in contrast to the “response to injury” hypothesis. 
The response to retention hypothesis postulated in 1995, states that the 
initiating step of atherosclerosis is the retention of lipoproteins within the 
vascular wall [112]. Intimal hyperplasia, or diffuse intimal thickening, is 
thought to expose proteoglycans. Lipoproteins bind to these exposed 
proteoglycans, thus promoting lipid retention in the vascular wall [113, 114]. 
Regardless of the exact initiator, a common feature of all these theories of 
atherosclerosis initiation is an early accumulation of oxidized LDL and 
macrophages in the intima. 
3.2.2 PROGRESSION OF ATHEROSCLEROSIS 
The majority of adults have some degree of atherosclerosis [115]. However, 
most atherosclerotic plaques are early or intermediate plaques which are 
asymptomatic. Formation of a necrotic core in atherosclerotic lesions is a 
crucial event because it marks the transition from a stable, clinically silent 
plaque into an advanced, unstable, plaque which may rupture, causing 
myocardial infarction or stroke [116, 117]. Therefore, it is of pivotal 
importance to elucidate the mechanisms promoting the death of macrophage 
foam cells in the plaque core. 
The most abundant cell type in advanced plaques is the macrophage foam cell. 
Macrophage foam cells contain an abundance of lipids, giving them a foam-
like look. Both hypoxia and inflammation trigger macrophages to shift their 
metabolism toward using glycolysis [118]. Glycolysis is much less energy-
efficient and promotes excessive consumption of glucose. Indeed, foam cells 
have been shown to have excessive consumption of glucose and oxygen [119, 
120]. 
Macrophages in the plaque may die via apoptosis or necrosis. Apoptosis is 
triggered by internal or external signals for the cell to self-destruct due to an 
overload of errors in cellular mechanisms or pathological behavior [121]. 
Apoptosis requires energy in the form of ATP and uses caspases to trigger cell 
death. A more uncontrolled form of cell death is called necrosis, where the 
cellular membrane starts leaking, resulting in cellular death. Apoptosis is 
favored in the presence of high intracellular ATP levels, while necrosis is 
favored when intracellular ATP levels are low [122]. If apoptotic cells are not 
properly cleared by other phagocytes, the cellular remains may start leaking, 
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which results in secondary necrosis [123]. The most common type of cell death 
in the human plaque core is necrosis [124]. 
3.2.3 ENERGY DEPLETION HYPOTHESIS 
Energy depletion (ATP depletion) in the plaque core may promote macrophage 
death. The energy depletion hypothesis was initially suggested based on 
observations of a large number of human plaques [125]. The theory states that 
when atherosclerosis progresses, the distances to oxygen and nutrient supplies 
increase. The intimal layer, previously supplied directly by the luminal blood, 
now have vast distances to oxygen and nutrient supply (Figure 7). In addition 
to increased diffusion distances, the energy demand of the plaque increases 
during the progression of atherosclerosis. Accumulation of macrophage foam 
cells with excessive consumption of both oxygen and glucose [126, 127] may 
decrease the availability of both oxygen and glucose in the plaque core. 
 
In support of the energy depletion hypothesis, hypoxia has been demonstrated 
in the cores of rabbit- [128, 129], mouse- [130] and human plaques [131]. 
Additionally, glucose and ATP deficiency have been demonstrated in the core 
of advanced rabbit plaques [126]. A combination of hypoxia and glucose 
deficiency results in ATP deficiency (137), which may drive necrotic core 
expansion. However, local concentrations of energy metabolites in different 
regions of human atherosclerotic plaques are not known.  
Figure 7 – The energy depletion hypothesis. As diffusion distances increase within the plaque, 
the cells close to the necrotic core experience energy failure. Reprinted from Leppänen et al. 
with permission [102]. 
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3.3 PAPER I 
 
In short, advanced plaques were collected from patients and snap-frozen in 
once piece. Bioluminescence imaging was chosen to measure energy 
metabolites due to its ability to provide spatial information of energy 
metabolite distribution [126]. Energy metabolites were measured in 
intermediate and advanced levels of each patient plaque. Next, levels of energy 
metabolites were compared assessed in different regions within advanced 
plaques. 
3.3.1 RESULTS 
ATP was measured and normalized against the number of cells in the viable 
intima of each plaque (Figure 8). The ATP/cell in the advanced plaques were 
only 1/10 of the intermediate plaques, indicating that they are severely ATP-
deficient (Figure 9C). The ATP deficiency is supported by a decreased level 
of extracellular glucose (Figure 9D) and intracellular glycogen (Figure 9E), 
indicating a deficiency in both energy supply and storage. As a consequence 
of hypoxia and high glycolysis, lactate levels are increased in the advanced 
plaques (Figure 9F). 
 
Figure 8 - Method overview. A. Oil red O section of an advanced plaque from the internal 
carotid artery (ICA). B. cellularity was assessed by fluorescence. C. ATP measurement by 
bioluminescence (unpublished image). Images assembled from Paper I, Ekstrand et al. [132]. 
In Paper I, the aim was: 
• To address the hypothesis that energy failure develops in 
the core of human advanced atherosclerotic plaques. 
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Figure 9 – Figure 2 of Paper I, Ekstrand et al. [132]. Depletion of ATP, glucose, and glycogen in 
advanced human plaques. A. Plaques were analyzed from the CCA (intermediate) and ICA 
(advanced). B. Measurements were made in the viable intima of each plaque. ATP/cell (C) 
glucose (D) and glycogen concentrations (E) were lower in advanced segments than in 
intermediate segments of the same plaque. Note logarithmic scale for ATP and glycogen. F. 
Lactate concentrations were higher in advanced segments of the plaque. n = 6, Wilcoxon 
Signed-Rank Test. 
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The viable intima, luminal zone, and perinecrotic zones of advanced plaques 
were marked (Figure 10). ATP/cell and extracellular glucose levels were 
significantly lower in the perinecrotic zone compared to the luminal zone 
(Figure 11). 
 
 
 
  
Figure 10 – Necrotic zones were identified (A, white arrows), after which viable intima was 
delineated (B). In the viable intima, the luminal zone and perinecrotic zones were marked. 
Images assembled from Paper I, Ekstrand et al. [132]. 
Figure 11 – Excerpt from Figure 3 of Paper I, Ekstrand et al. [132] Severe depletion of ATP and 
glucose in perinecrotic zone of advanced plaques. Lower concentrations of ATP (B) and glucose 
(C) were measured in the perinecrotic zone compared to the luminal zone (p<0.05). n = 6, 
paired t-test. 
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3.3.2 DISCUSSION 
In Paper I, we demonstrate that energy metabolites (ATP, glucose, glycogen) 
are depleted in advanced human atherosclerotic plaques. Within advanced 
plaques, energy metabolites (ATP, glucose) are most depleted close to the 
necrotic core. This data supports the hypothesis that ATP depletion develops 
in the core of advanced human atherosclerotic plaques, and may contribute to 
necrotic core expansion. 
We demonstrate reduced availability of glucose and accumulation of lactate in 
advanced plaques compared to intermediate plaques. In agreement with our 
results, Tomas et al. [133] performed metabolic profiling of plaque 
homogenates and demonstrated decreased glucose availability and lactate 
accumulation in vulnerable plaques. However, ATP levels were not found to 
be different between vulnerable and more stable plaques in their study. ATP 
concentrations varied greatly between plaques and spanned a tenfold range. 
We found a similar wide range of ATP concentrations between plaques in our 
study (Figure 9C; note logarithmic scale). However, we did find significant 
differences in ATP levels when intermediate and advanced parts of each 
patient were compared (Figure 9C). Also, and more importantly, ATP levels 
were significantly lower in the perinecrotic zone compared to the luminal zone 
within advanced plaques (Figure 11B). The wide range of ATP levels between 
different patients probably reflects different degrees of ATP hydrolysis 
depending on the time required for dissection during surgery. 
ATP is the fuel driving almost all energy-requiring cellular processes. In 
atherosclerosis, it is particularly interesting that key events in lipid clearing are 
directly dependent on ATP, such as reverse cholesterol transport, cellular 
mobility, and efferocytosis (clearing of dead cells). A reduced reverse 
cholesterol transport results in an increased cholesterol load on the cells, 
paradoxically putting them under increased ATP demand where cholesterol is 
hydrolyzed and re-esterified, consuming 1 ATP per 2 cholesterol every 24 
hours [134]. Likewise, a decrease in cellular movement and efferocytosis will 
decrease the ability of the plaque to be cleared of lipids and cellular debris by 
outmigration of macrophages. ATP-deficient cells may become necrotic, or 
promote necrosis over apoptosis [122], thus facilitating necrotic core 
expansion. 
Interestingly, patients with obstructive sleep apnea (OSA) have periods of 
hypoxia and reoxygenation while sleeping, which causes intermittent hypoxia 
(IH). Patients with IH are shown to have a higher prevalence of atherosclerosis 
[135]. Giving rabbits and mice with atherosclerosis hyperbaric treatment 
(pressure chamber with high oxygen levels) reverses atherosclerosis by 
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decreasing lipid oxidation, decreasing inflammation, increasing antioxidant 
levels [136, 137], as well as increasing efferocytosis [138]. Indeed, giving 
patients with diabetic feet hyperbaric treatment improved their atherosclerosis 
[139]. These data suggest that hypoxia promotes atherosclerosis progression 
and that improving plaque oxygenation may reverse atherosclerosis, possibly 
by restoring ATP levels and energy balance within the plaque. Increased ATP 
levels would improve the viability of plaque cells, enabling them to perform 
tasks such as reverse cholesterol transport, efferocytosis, and outmigration, 
allowing the plaque to heal. 
Finally, an increase in lactate levels means the pH of the advanced plaque 
decreases. A lower pH increases the likelihood of LDL aggregation, fusion and 
lipid droplet formation [140], which increases its affinity for binding to 
proteoglycans of the arterial intima [141], which in turn is a driver for 
atherosclerosis. Acidic pH increases the oxidative modification of LDL and 
downregulates the expression of ABCA1, which is needed for reverse 
cholesterol transport [142]. 
3.3.3 CORRECTIONS 
As seen in Figure 1 in Paper I, some statistics were incorrectly based on a 
Student’s T-test, which assumes parametric unpaired data, instead of Wilcoxon 
signed-rank test, which assumes nonparametric paired data. Corrections for 
Figure 1 are provided here; Figure 1C macrophages (p=0.0313), and smooth 
muscle cells (p=0.2188), Figure 1D cellularity (p=0.4375) and necrotic area 
(p=0.0313). None of these corrections change the level of significance, nor the 
conclusions of the Paper. 
  
Energy metabolism and angiogenesis in atherosclerosis and cancer 
34 
3.4 REACTIVE OXYGEN SPECIES IN 
ATHEROSCLEROSIS 
ROS are reactive compounds that are formed during metabolism or by specific 
enzymes. ROS are part of cellular signaling [44], but an excess may have 
pathological effects. There are several types of ROS present inside and outside 
cells, and they are neutralized through different protective mechanisms to limit 
their potential deleterious effects [44]. Some of the most important enzymes in 
protecting against ROS are SOD [56], catalase [57], and glutathione 
peroxidases (GPx) [59, 60]. 
High ROS levels are present in atherosclerosis and are part of the inflammatory 
response, oxidative modification of LDL, and proliferation signaling [143]. 
Depending on the location of excessive ROS, it can have different deleterious 
effects. Intracellular ROS may damage DNA, proteins, lipids, and 
carbohydrates [53]. Extracellular ROS oxidizes lipoproteins and activates 
matrix metalloproteinases [144]. Oxidation of LDL results in an increase of 
pro-atherogenic properties. Once macrophages detect oxidized LDL, they 
trigger chronic inflammation, which in turn increases recruitment of immune 
cells [145]. Extracellular ROS also increases adhesion of leukocytes to 
endothelium, meaning that immune cells are recruited from the blood to sites 
where ROS is present [63]. 
There is no non-invasive technique that allows arterial ROS to be determined 
in vivo. Fixed or frozen material does not reflect the in vivo situation since ROS 
has a half-life of milliseconds. Additionally, current methods to assess arterial 
ROS do not discriminate between intracellular- and extracellular ROS. We 
introduce a technique that allows real-time visualization and quantification of 
ROS in intact aortas incubated under in vivo like conditions. Our technique 
utilizes the ROS-sensitive luminescent probes luminol and isoluminol. 
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3.5 PAPER II 
 
In short, we established a bioluminescence imaging method with ROS probes 
for intracellular or extracellular ROS measurement in living mouse aortas ex 
vivo. Intracellular and extracellular ROS was correlated against macrophage 
and smooth muscle cell content. ROS levels were measured before, during, and 
after atherosclerotic lesion development to assess at which time point ROS 
levels increase. Finally, atherosclerotic mice were treated for 5 days with high 
dose atorvastatin or lipid-lowering by diet, after which intracellular and 
extracellular ROS was measured. 
  
In Paper II, the aims were: 
• To investigate if intracellular and extracellular levels of 
reactive oxygen species (ROS) within the mouse aorta 
increase before or after diet-induced lesion formation. 
• To investigate if intracellular and extracellular ROS 
correlates to cell composition in atherosclerotic lesions. 
• To investigate if intracellular and extracellular ROS 
levels within established atherosclerotic lesions can be 
reduced through lipid-lowering by diet or atorvastatin. 
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3.5.1 RESULTS 
We established a method for assessing intracellular and extracellular ROS 
separately in living female Apoe−/− mouse aortas (Figure 12). The presence of 
smooth muscle and macrophages was measured with immunostaining. 
Intracellular ROS was shown to correlate with macrophages, and extracellular 
ROS correlates with smooth muscle (data not shown). 
 
  
Figure 12 - Figure 1 from Paper II, Ekstrand et al. [146]. A. Living aortas were placed in an organ 
bath below a photon-counting camera. B. Photon counting images of two aortas. The left aorta 
has extensive atherosclerosis, while the right one has limited atherosclerosis. C. Luminescence 
(y-axis) over time (x-axis) in the aortic arch (red line) and background (blue line). Isoluminol is 
not cell-permeable, while luminol is cell-permeable. D. Addition of SOD and catalase marks 
quenching of extracellular ROS. Difference between quenched signal and isoluminol signal 
marks extracellular ROS. Addition of luminol to the quenched extracellular signal marks 
intracellular signal. 
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Measuring ROS-levels in the aorta during different times of atherosclerosis 
development revealed that after 7 weeks of western diet, mice developed 
visible atherosclerotic lesions that were high in both intracellular and 
extracellular ROS (Figure 13). After 3 weeks of western diet, before the 
development of visible atherosclerotic lesions, intracellular ROS was increased 
(red box), while extracellular ROS was still low (blue box). 
 
Treating atherosclerotic mice with high-dose atorvastatin for 5 days decreased 
both intracellular and extracellular ROS levels (Figure 14). This effect does 
not correlate with either plasma cholesterol nor plasma triglyceride levels. 
Lipid-lowering by diet for 5 days had no effect on ROS levels within the aortic 
arch (Figure 15). 
Figure 13 - Excerpt from Figure 2 of Paper II, Ekstrand et al. [146]. After 3 weeks of western 
diet, intracellular ROS increased despite no visible lesions being present (red box), while 
extracellular ROS was still low (blue box). n = 6–7 in each group. *p>0.05 vs chow diet, One-
way ANOVA with Dunnett’s multiple comparison test. 
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Figure 14 – Excerpt from Figure 6 of Paper II, Ekstrand et al. [146] Atorvastatin reduces 
intracellular and extracellular ROS levels within the atherosclerotic aortic arch. n = 6 in each 
group. **p<0.01 vs vehicle, *p<0.05 vs vehicle. One sample t-test (C and D). 
Figure 15 – Figure 4 of Paper II, Ekstrand et al. [146]. Lipid lowering by diet does not affect 
ROS levels within the atherosclerotic aortic arch. (A) Intracellular and extracellular ROS were 
assessed in the atherosclerotic arch (red). (B) Lipid lowering by diet did not affect intracellular 
ROS. (C) Lipid lowering by diet did not affect extracellular ROS. NS — non-significant. One 
sample t-test. n = 6 in each group. 
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3.5.2 DISCUSSION 
In Paper II, we established a method of measuring intracellular and 
extracellular ROS individually in living mouse aortas ex vivo. We 
demonstrated that intracellular ROS correlates with smooth muscle cells, and 
extracellular ROS correlates with macrophages. Further, we provided evidence 
of an increase in intracellular ROS before the development of visible lesions. 
Finally, short-term atorvastatin treatment decreased both intracellular and 
extracellular ROS, while lipid-lowering by diet did not. 
The increase of intracellular ROS before the development of atherosclerosis in 
the descending aorta of mice is interesting. This finding is in line with 
observations that mitochondrial DNA damage occurs before the development 
of lesions in Apoe−/− mice [147]. Additionally, intracellular ROS in smooth 
muscle has been connected to the development of atherosclerosis [148]. 
However, our results connect intracellular ROS to macrophages, and not 
smooth muscle. An increase of intracellular ROS in macrophages before lesion 
development could be due to intracellular oxidation of LDL by lipoxygenases 
such as 15-lipoxygenase-2 (15-LOX-2) [149]. 15-LOX-2 is upregulated in 
macrophage-rich areas of carotid plaques and is connected to an increased LDL 
oxidation in macrophages [150]. Further, 15-LOX-2 has been reported to 
increase expression of ROS via Nox-enzymes [151, 152], possibly making it a 
part of atherosclerosis development. 
The reduction of both intracellular and extracellular ROS by atorvastatin was 
independent of lipid-lowering, plaque composition, or inflammation. The high 
dose of atorvastatin and short treatment ensures that overall plaque 
composition is not changed, and the inflammatory signature of the plaque 
remained stable (Figure 5 of Paper II). These results are in accordance with 
previous results by Wassmann et al. [153], where they demonstrate 
downregulation of Nox1 and upregulation of catalase expression in response 
to atorvastatin treatment, decreasing the overall ROS presence in 
atherosclerotic rat aorta. 
Our results that lipid-lowering by diet does not change ROS is in contrast to 
previous research by Aikawa et al. [154], where a lipid-lowering diet decreased 
ROS in rabbit atherosclerotic aortas. The main difference between our studies 
is the treatment duration. Aikawa et al. gave a lipid-lowering diet for 16 
months, whereas we gave it for 5 days. High lipid levels and LDL binding to 
the intima are crucial processes in the development of atherosclerosis. 
However, in the advanced plaque, there already exists a large pool of oxidized 
LDL, and a decreased influx of non-oxidized LDL is most likely not sufficient 
to change ROS signaling in 5 days. 
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4 ANGIOGENESIS IN CANCER 
In 1971, Judah Folkman proposed the hypothesis that cancer growth could be 
stopped by inhibiting blood vessel growth [155]. Despite a massive amount of 
research into angiogenesis inhibition, current angiogenesis inhibitors have 
only limited effect in most cancers [156, 157]. However, antiangiogenic drugs 
work well in many mouse models [158]. 
There are two forms of angiogenesis, sprouting and intussusceptive 
angiogenesis. Sprouting angiogenesis is widely studied, whereas 
intussusceptive angiogenesis is largely enigmatic. Current antiangiogenic 
drugs target the sprouting pathway, with VEGF and its receptors being the 
most common targets [159, 160]. It is possible that intussusceptive 
angiogenesis also promotes the growth of human tumors. However, the role of 
intussusceptive angiogenesis in human cancer is understudied. 
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4.1 PAPER III 
 
In short, biopsies of human malignant melanoma metastases and mouse 
melanomas were systematically analyzed for the presence of intravascular 
pillars using epifluorescence and confocal microscopy. In addition, we used a 
3D co-culture cell system to study mechanisms of pillar formation with the 
further purpose of identifying potential inhibitors of intussusceptive 
angiogenesis. 
4.1.1 RESULTS 
Strikingly, we found evidence of intussusceptive angiogenesis in all human 
melanoma metastases in our study (Figure 2 and Figure 3 of Paper III). Our 
finding indicates that angiogenesis in human tumors is, partly, dependent on a 
previously virtually ignored mechanism. 
Next, we studied the presence of intussusceptive angiogenesis in two mouse 
models of malignant melanoma, namely a PDX (Patient-Derived Xenograft) 
[161] model, and a BPT (BrafCA/+Ptenf/fTyrosinase-Cre) model [162]. No signs 
of intussusceptive pillars were detected in either mouse model (Figure 4 of 
Paper III). 
Finally, we established a 3D co-culture model which spontaneously develops 
pillars (figure 5 of Paper III). Using MMP inhibitors, pillar formation is 
stopped, and smooth muscle cell movement inside pillars was impaired (Figure 
6 of Paper III). 
  
In Paper III the aims were: 
• To address the hypothesis that intussusceptive 
angiogenesis promotes growth of human tumors. 
• To establish a model to elucidate the cellular and 
molecular mechanisms behind intussusceptive 
angiogenesis with the further aim of identifying potential 
drug targets. 
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4.1.2 DISCUSSION 
We demonstrate signs of intussusceptive angiogenesis in human malignant 
melanoma metastases. Previously, evidence of intussusceptive angiogenesis in 
human cancer was weak, consisting only of intraluminal structures or vascular 
invaginations shown by brightfield microscopy [163-165]. Having identified 
and 3D-reconstructed intussusceptive pillars, they contain the same elements 
as those that form during development. In this regard, our study provides the 
first verification of intussusceptive angiogenesis in human cancer. 
While we can show the presence of intussusceptive angiogenesis, we cannot 
currently quantify the extent or importance of it. However, the bare fact of its 
existence as a parallel mechanism to sprouting angiogenesis in cancer is reason 
enough to treat it as a major player in resistance against current antiangiogenic 
therapy. 
The fact that no pillars were found in two mouse melanoma models needs to 
be addressed. There are fundamental differences between mouse models of 
cancer and human cancer since VEGF inhibitors work well in mice but have 
marginal effects in humans [158]. One of the mouse models tested is a patient-
derived xenograft (PDX) [161] model, which lacks an immune system. While 
the lack of an immune system is a prerequisite for the model as such to work, 
it may also interfere with the potential need of recruiting bone marrow-derived 
cells (BMDCs) for intussusceptive angiogenesis to take place [92]. In the 
genetic BrafCA/+Ptenf/fTyrosinase-Cre (BPT) model [162], tumor formation is 
genetically triggered, after which tumors rapidly grow and metastasize. This 
rapid growth may result in tumors not vascularized enough to trigger the 
intussusceptive phase of angiogenesis. Having access to a mouse model of 
cancer containing intussusceptive angiogenesis should be a priority for future 
research on angiogenesis inhibitors. 
3D cell culture models are being used more commonly within research [166]. 
To study the mechanisms of pillar development, we 3D co-cultured 
endothelium and smooth muscle together [167], enabling them to express basic 
cellular mechanisms which would be impossible in either monoculture or 2D-
cell culture. When cultured together, the cells create tubes (reminiscent of 
vasculogenesis), tip cells (reminiscent of sprouting angiogenesis), as well as 
pillars (reminiscent of intussusceptive angiogenesis). We theorize that the 
endothelial monolayer on top of the smooth muscle mimics the inside of a 
blood vessel, enabling the cellular program for pillar formation. Since the 
pillars in our cell model are structurally similar to the intussusceptive pillar, 
they may share basic cellular mechanisms for their formation, making the 
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system suitable for studying basic mechanisms of intussusceptive 
angiogenesis. 
In summary, in this paper, we describe the first verified proof for 
intussusceptive angiogenesis in human malignant melanoma. The presence of 
intussusceptive angiogenesis in human cancer indicates the need for new 
therapeutics which target not only sprouting angiogenesis but also 
intussusceptive angiogenesis in combination. Developing a mouse model 
reflecting human cancer angiogenesis is essential to studying the 
antiangiogenic treatment of the future, and suggestions for mechanisms to 
target can be found in our cell model of intussusceptive angiogenesis. 
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5 METHODOLOGICAL CONSIDERATIONS 
In this section, I will briefly discuss the selection of methods used in the 
different Papers. 
5.1 BIOLUMINESCENCE IMAGING 
Bioluminescence is the emission of light from living organisms [168]. 
Bioluminescence imaging involves using bioluminescent enzymes to visualize 
substrates within living tissue or animals (Figure 16). 
 
5.1.1 BIOLUMINESCENCE IMAGING OF ENERGY 
METABOLITES 
Bioluminescence imaging of energy metabolites enables the quantification of 
energy metabolites in frozen tissue sections with a resolution of 50-100 µm 
[102]. It is, in essence, an in vitro method but analysis of snap-frozen tissue 
reflects the in vivo situation. The advantage of the technique, compared to 
analysis of tissue homogenates, is the high spatial resolution. Bioluminescence 
imaging of energy metabolites utilizes enzymes such as luciferase from 
fireflies or bacteria to produce light [102, 169]. 
In Paper I, we used bioluminescence imaging of energy metabolites on heat-
inactivated sections from human atherosclerotic plaques. The measurement of 
energy metabolites uses a mix of enzymes and substrates to accommodate the 
breakdown of the energy metabolite of interest, resulting in the release of 
Figure 16 - Schematic image of bioluminescence imaging. 
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photons (Figure 17). A common combination of enzymes containing bacterial 
luciferase, G6PDH, and NAD(P)H-FMN oxidoreductase, which is used in 
several pathways, is marked in light blue. 
 
Figure 17 - Enzymatic pathways used for measuring energy metabolites in bioluminescence 
imaging of energy metabolites. Enzymes are colored orange. 
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5.1.2 BIOLUMINESCENCE IMAGING OF REACTIVE 
OXYGEN SPECIES 
In Paper II, the ROS probes luminol and isoluminol were used to measure 
intracellular and extracellular ROS, respectively, in living mouse aorta ex vivo. 
The probes emit photons when they are oxidized by ROS, which can then be 
registered by the photon camera. 
Luminol and isoluminol are probes for ROS, reacting with superoxide [170], 
hydrogen peroxide [171], hypochlorous acid [172], peroxynitrite [173], and 
peroxyl radicals [174].  
Luminol pass cell membranes (luminol), while isoluminol does not, which 
enabled individual measurement of intracellular- and extracellular ROS in the 
same sample. Correction for background signal was made by adding SOD and 
catalase to scavenge extracellular ROS, enabling quantification of intracellular 
and extracellular signals separately. Ideally, the same procedure should be used 
for intracellular ROS signal; however, delivering SOD and catalase 
intracellularly through liposomes, in our experience, results in clouding of the 
medium, distorting ROS measurements. 
5.2 ANIMAL MODELS 
In Paper II, we used female Apoe−/− mice to study ROS during the development 
of atherosclerosis. Apoe−/− mice are deficient in apolipoprotein E (ApoE), used 
in lipoprotein transport, and the ApoE deficiency results in 
hypercholesterolemia [175]. 
Mouse dietary models of atherosclerosis do not develop advanced lesions [176, 
177]. Therefore, genetic models are used to study atherosclerosis development 
[178]. Since mouse plaques are smaller than human plaques, hypoxia is less 
prevalent due to shorter diffusion distances, and neovascularization of the 
intima is uncommon [176] while it is common in human plaques [179], making 
the study of energy metabolism challenging. Additionally, mouse plaques are 
rarely unstable [180]. 
In Paper III, we studied angiogenesis in two mouse models of malignant 
melanoma to assess the presence of intussusceptive angiogenesis.  
The first model studied was a PDX model [161]. In the PDX model, mice 
without a functioning immune system are injected with human tumor cells 
subcutaneously, which subsequently grew as a single tumor. The major 
strength of this model is that the cancer cells are human, and the drawback is 
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the lack of an immune system. The lack of an immune system may interfere 
with intussusceptive angiogenesis due to the lack of recruitment of BMDCs, 
which may be required for intussusceptive angiogenesis [92]. 
The second model studied used a BrafCA/+Ptenf/fTyrosinase-Cre (BPT) model 
[162]. In the BPT model, tumor formation is initiated by the topical application 
of 4-hydroxytamoxifen, which genetically activates BRAF600VE expression and 
inactivates PTEN expression. This makes melanocytes acquire tumor 
characteristics, inducing a rapid growth and formation of metastases. The 
benefit of this model is that tumor cells behave like human tumors, forming 
metastases. The drawback is that the model is based on a few key mutations, 
while normal tumors have thousands of mutations [181]. Additionally, the 
rapid growth of the tumors is possibly causing them not to be vascularized 
enough to enter the intussusceptive phase of vessel expansion. 
5.3 3D CELL CULTURE MODELS 
Cell culture models are useful for studying basic cell behavior and dynamics 
in an artificial environment in vitro (in the glass). In vivo (within the living), 
cells grow in a three-dimensional manner and interact with a variety of other 
cells, both sending and receiving signals that affect cell behavior [182]. 
The most basic cell culture systems are 2D. All cells are polarized toward the 
plastic surface of the dish in which they grow, making cell-cell interactions 
very limited. 2D cell cultures also prevent the cells from forming the structures 
they do in vivo, such as spheres [183] and tubes [184], which is possible in 3D 
cell cultures. The main benefit of 3D cell cultures is that cells behave more in 
vivo-like compared to 2D cell cultures. 
Traditionally, cells have been cultured in a monoculture, consisting of only one 
cell type. Most organs in the body consist of two or more cell types which 
interact to achieve both form and function [185]. Culturing two or more cell 
types together is called co-culture, and doing so brings the system closer to 
how the cells would behave in vivo [186]. By combining 3D cell culture and 
co-culture, we get a 3D co-culture model where two cell types are free to 
interact in any spatial direction. 
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5.4 LIVE-CELL IMAGING 
Live-cell imaging, or time-lapse microscopy, is a system where images of cells 
are taken at certain intervals to track movement and other events during a 
longer period [187]. Live-cell imaging is a useful tool to understand cellular 
interactions and movement since a still image provides no information on the 
cell migration pattern, or how it is interacting with other cells. A series of still 
images can be made into a movie, which enables visual observation of cellular 
behavior. 
Live-cell imaging requires cells to be placed under a microscope during an 
extended time. Microscopes are normally not contained within a fully 
functional cell culture incubator, meaning that cells in live-cell imaging are in 
an environment different from their normal culture conditions. A live-cell 
imaging microscope may include a makeshift incubator to support temperature 
control, and in some cases, even a controlled atmosphere. In our 3D co-culture 
experiments, cells are contained within a temperature-controlled incubator 
with normal atmospheric composition. The pH-regulation normally supported 
by the high carbon dioxide levels of cell culture incubators was instead 
supported by the addition of HEPES to the cell culture medium. 
During live-cell imaging, cells are repeatedly exposed to light of different 
wavelengths to visualize Celltracker Green and Orange. This light exposure 
may have some effect on cell viability or behavior of the cells, seeing as most 
live-cell imaging include the risk of phototoxicity [188]. However, any 
potential phototoxicity should be similar between the groups used in our 
experiments. 
5.5 IMMUNOFLUORESCENCE 
Immunofluorescence is a method where antibodies labeled with fluorochromes 
directly or indirectly are used to label specific structures in a section of tissue 
or cells. The labeling can be identified through the use of epifluorescence 
microscopy (two dimensional) or confocal microscopy (three dimensional), to 
explore the distribution of these structures of interest in comparison to each 
other. Immunofluorescence is often coupled with image analysis to quantify 
the captured signals.  
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6 CONCLUSIONS AND CLINICAL 
PERSPECTIVES 
This thesis has explored some of the effects that originate from hypoxia, 
deranged energy metabolism, reactive oxygen species, and angiogenesis. 
In Paper I, we present evidence of energy deficiency in advanced human 
atherosclerotic plaques, and the energy deficiency was most severe close to the 
necrotic core. This knowledge can be used to target energy-consuming 
processes or increase energy supply to aid healing of the plaque. 
In Paper II, we present evidence of ROS-levels rising before the development 
of visible atherosclerotic lesions in mice, and that atorvastatin has a ROS-
lowering effect which is independent of lipid levels. This knowledge may be 
used to better understand how atherosclerosis develops and the mechanisms 
behind the atheroprotective effect of atorvastatin. 
In Paper III, we present the first evidence of intussusceptive angiogenesis in 
human cancer. This knowledge could help explain the limited clinical 
effectiveness of current angiogenesis inhibitors which target only sprouting 
angiogenesis. Combining the inhibition of both sprouting and intussusceptive 
angiogenesis should be explored as a treatment option to prevent tumor 
growth. 
In summary, this thesis provides new insights into the effects of hypoxia and 
deranged energy metabolism. In combination with future research, these 
results may help establish new treatments for atherosclerosis and cancer.
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